ATX-101 is currently in late stage clinical trials for the reduction of submental fat, which commonly presents as a double chin. It is a proprietary formulation of a purified synthetic version of deoxycholic acid, a naturally occurring molecule in the body that aids in the breakdown of dietary fat.1 If approved, ATX-101 will be a first-in-class submental contouring injectable drug.
While the submental region, or area under the chin, is visually important to patients, it is often undertreated. There is currently no FDA-approved injectable drug to reduce fat under the chin. Read More
ATX-101 treatment contours the area under the chin by destroying fat cells, while leaving surrounding tissue largely unaffected.2 After ATX-101 causes targeted destruction of fat cells, a natural healing response follows that involves clearing cellular debris.2 This response may also include new collagen formation,2 known as neocollagenesis, in the treatment area. Read More
For the past six years, ATX-101 has been the focus of a global clinical development program that has enrolled more than 2,500 patients worldwide, of which more than 1,600 have been treated with ATX-101.2 In clinical trials, ATX-101 resulted in a reduction of fat under the chin, with more than 90% of patients in a long-term follow-up study of treatment responders maintaining a meaningful reduction of the fat after two years.2 Additionally, the majority of clinical trial participants have reported high satisfaction with their treatment and the improvements in their appearance and self-perception.2 Read More
1 Stryer L. Biosynthesis of membrane lipids and steroids. In: Biochemistry. New York, NY: WH Freeman and Co; 1995:691-707.
2 Kythera Data on File